header advert
Results 1 - 2 of 2
Results per page:
The Bone & Joint Journal
Vol. 103-B, Issue 7 | Pages 1197 - 1205
1 Jul 2021
Magill P Hill JC Bryce L Martin U Dorman A Hogg R Campbell C Gardner E McFarland M Bell J Benson G Beverland D

Aims

A typical pattern of blood loss associated with total hip arthroplasty (THA) is 200 ml intraoperatively and 1.3 l in the first 48 postoperative hours. Tranexamic acid (TXA) is most commonly given as a single preoperative dose only and is often withheld from patients with a history of thromboembolic disease as they are perceived to be “high-risk” with respect to postoperative venous thromboembolism (VTE). The TRanexamic ACid for 24 hours trial (TRAC-24) aimed to identify if an additional 24-hour postoperative TXA regime could further reduce blood loss beyond a once-only dose at the time of surgery, without excluding these high-risk patients.

Methods

TRAC-24 was a prospective, phase IV, single centre, open label, parallel group, randomized controlled trial (RCT) involving patients undergoing primary unilateral elective THA. The primary outcome measure was the indirect calculated blood loss (IBL) at 48 hours. The patients were randomized into three groups. Group 1 received 1 g intravenous (IV) TXA at the time of surgery and an additional oral regime for 24 hours postoperatively, group 2 only received the intraoperative dose, and group 3 did not receive any TXA.


Orthopaedic Proceedings
Vol. 102-B, Issue SUPP_5 | Pages 11 - 11
1 Jul 2020
Magill P Hill J Bryce L Dorman A Hogg R Campbell C Benson G Beverland D
Full Access

Background

91% of blood loss in Total Hip Replacement (THR) occurs in the period after skin closure and the first 24 post-operative hours. TRAC-24 was established to identify if an additional 24-hour post-operative oral regime of Tranexamic acid (TXA) is superior to a once-only intravenous dose at surgery.

Methods

This was a prospective, phase IV, single centered, open label, parallel group controlled trial on patients undergoing primary elective THR. A history of thromboembolic or cardiovascular disease were not exclusion criteria. The primary outcome was indirect calculated blood loss at 48 hours (IBL). 534 patients were randomized on a 2:2:1 ratio over three different groups. Group 1 received an intravenous dose of TXA at the time of surgery and an additional 24-hour post-operative oral regime, Group 2 only received the intra-operative dose and Group 3 did not receive any TXA.